The role of high-dose chemotherapy and stem-cell transplantation in patients with multiple myeloma: A practice guideline of the cancer care Ontario practice guidelines initiative

Kevin Imrie, Rosmin Esmall, Ralph M. Meyer, H. Abu Zahra, L. Baig, I. Chin-Yee, B. Costello, R. M. Crump, C. DeMetz, H. Dhaliwal, R. Esmail, P. Galbraith, S. Gluck, M. Gospodarowicz, L. Huebsch, K. Imrie, M. Kacsor, L. Kaizer, C. T. Kouroukis, J. MacEachernJ. Matthews, J. Meharchand, H. Messner, C. Sawka, N. Shehata, A. Smith, I. Walker, K. Yee

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The Hematology Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative has systematically reviewed the published literature and, through a consensus process, developed an evidence-based practice guideline assessing the role of stem-cell transplantation in patients with multiple myeloma. The conclusions were validated by solicited feedback from 221 practitioners across Ontario, Canada. The guideline comprises six recommendations: 1) Autologous transplantation is recommended for patients with stage II or III myeloma and good performance status. Evidence of benefit is strongest for patients who are younger than 55 years of age and have a serum creatinine level less than 150 μmol/L (<1.7 mg/dL). Physicians must use clinical judgment in recommending transplantation to other patients. 2) Allogeneic transplantation is not recommended as routine therapy. 3) Patients potentially eligible for transplantation should be referred for assessment early after diagnosis and should not be extensively exposed to alkylating agents before collection of stem cells. 4) Autologous peripheral blood stem cells should be harvested early in the patient's treatment course. The best available data suggest that transplantation is most advantageous when performed as part of initial therapy. 5) The comparative data addressing the specifics of the transplantation process are insufficient to allow definitive recommendations. In the absence of such data, a single transplant with high-dose melphalan, with or without total-body irradiation, is suggested for patients undergoing transplantation outside a clinical trial. 6) At this time, no conclusions can be reached about the role of interferon therapy after transplantation.

Original languageEnglish
Pages (from-to)619-629
Number of pages11
JournalAnnals of Internal Medicine
Volume136
Issue number8
StatePublished - Apr 16 2002
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Ontario
Multiple Myeloma
Practice Guidelines
Transplantation
Drug Therapy
Neoplasms
Melphalan
Autologous Transplantation
Whole-Body Irradiation
Evidence-Based Practice
Alkylating Agents
Homologous Transplantation
Hematology
Therapeutics
Interferons
Canada
Early Diagnosis
Creatinine
Consensus

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The role of high-dose chemotherapy and stem-cell transplantation in patients with multiple myeloma : A practice guideline of the cancer care Ontario practice guidelines initiative. / Imrie, Kevin; Esmall, Rosmin; Meyer, Ralph M.; Abu Zahra, H.; Baig, L.; Chin-Yee, I.; Costello, B.; Crump, R. M.; DeMetz, C.; Dhaliwal, H.; Esmail, R.; Galbraith, P.; Gluck, S.; Gospodarowicz, M.; Huebsch, L.; Imrie, K.; Kacsor, M.; Kaizer, L.; Kouroukis, C. T.; MacEachern, J.; Matthews, J.; Meharchand, J.; Messner, H.; Sawka, C.; Shehata, N.; Smith, A.; Walker, I.; Yee, K.

In: Annals of Internal Medicine, Vol. 136, No. 8, 16.04.2002, p. 619-629.

Research output: Contribution to journalArticle

Imrie, K, Esmall, R, Meyer, RM, Abu Zahra, H, Baig, L, Chin-Yee, I, Costello, B, Crump, RM, DeMetz, C, Dhaliwal, H, Esmail, R, Galbraith, P, Gluck, S, Gospodarowicz, M, Huebsch, L, Imrie, K, Kacsor, M, Kaizer, L, Kouroukis, CT, MacEachern, J, Matthews, J, Meharchand, J, Messner, H, Sawka, C, Shehata, N, Smith, A, Walker, I & Yee, K 2002, 'The role of high-dose chemotherapy and stem-cell transplantation in patients with multiple myeloma: A practice guideline of the cancer care Ontario practice guidelines initiative', Annals of Internal Medicine, vol. 136, no. 8, pp. 619-629.
Imrie, Kevin ; Esmall, Rosmin ; Meyer, Ralph M. ; Abu Zahra, H. ; Baig, L. ; Chin-Yee, I. ; Costello, B. ; Crump, R. M. ; DeMetz, C. ; Dhaliwal, H. ; Esmail, R. ; Galbraith, P. ; Gluck, S. ; Gospodarowicz, M. ; Huebsch, L. ; Imrie, K. ; Kacsor, M. ; Kaizer, L. ; Kouroukis, C. T. ; MacEachern, J. ; Matthews, J. ; Meharchand, J. ; Messner, H. ; Sawka, C. ; Shehata, N. ; Smith, A. ; Walker, I. ; Yee, K. / The role of high-dose chemotherapy and stem-cell transplantation in patients with multiple myeloma : A practice guideline of the cancer care Ontario practice guidelines initiative. In: Annals of Internal Medicine. 2002 ; Vol. 136, No. 8. pp. 619-629.
@article{2c32d56435dd40fda52173a1c7c168b0,
title = "The role of high-dose chemotherapy and stem-cell transplantation in patients with multiple myeloma: A practice guideline of the cancer care Ontario practice guidelines initiative",
abstract = "The Hematology Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative has systematically reviewed the published literature and, through a consensus process, developed an evidence-based practice guideline assessing the role of stem-cell transplantation in patients with multiple myeloma. The conclusions were validated by solicited feedback from 221 practitioners across Ontario, Canada. The guideline comprises six recommendations: 1) Autologous transplantation is recommended for patients with stage II or III myeloma and good performance status. Evidence of benefit is strongest for patients who are younger than 55 years of age and have a serum creatinine level less than 150 μmol/L (<1.7 mg/dL). Physicians must use clinical judgment in recommending transplantation to other patients. 2) Allogeneic transplantation is not recommended as routine therapy. 3) Patients potentially eligible for transplantation should be referred for assessment early after diagnosis and should not be extensively exposed to alkylating agents before collection of stem cells. 4) Autologous peripheral blood stem cells should be harvested early in the patient's treatment course. The best available data suggest that transplantation is most advantageous when performed as part of initial therapy. 5) The comparative data addressing the specifics of the transplantation process are insufficient to allow definitive recommendations. In the absence of such data, a single transplant with high-dose melphalan, with or without total-body irradiation, is suggested for patients undergoing transplantation outside a clinical trial. 6) At this time, no conclusions can be reached about the role of interferon therapy after transplantation.",
author = "Kevin Imrie and Rosmin Esmall and Meyer, {Ralph M.} and {Abu Zahra}, H. and L. Baig and I. Chin-Yee and B. Costello and Crump, {R. M.} and C. DeMetz and H. Dhaliwal and R. Esmail and P. Galbraith and S. Gluck and M. Gospodarowicz and L. Huebsch and K. Imrie and M. Kacsor and L. Kaizer and Kouroukis, {C. T.} and J. MacEachern and J. Matthews and J. Meharchand and H. Messner and C. Sawka and N. Shehata and A. Smith and I. Walker and K. Yee",
year = "2002",
month = "4",
day = "16",
language = "English",
volume = "136",
pages = "619--629",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "8",

}

TY - JOUR

T1 - The role of high-dose chemotherapy and stem-cell transplantation in patients with multiple myeloma

T2 - A practice guideline of the cancer care Ontario practice guidelines initiative

AU - Imrie, Kevin

AU - Esmall, Rosmin

AU - Meyer, Ralph M.

AU - Abu Zahra, H.

AU - Baig, L.

AU - Chin-Yee, I.

AU - Costello, B.

AU - Crump, R. M.

AU - DeMetz, C.

AU - Dhaliwal, H.

AU - Esmail, R.

AU - Galbraith, P.

AU - Gluck, S.

AU - Gospodarowicz, M.

AU - Huebsch, L.

AU - Imrie, K.

AU - Kacsor, M.

AU - Kaizer, L.

AU - Kouroukis, C. T.

AU - MacEachern, J.

AU - Matthews, J.

AU - Meharchand, J.

AU - Messner, H.

AU - Sawka, C.

AU - Shehata, N.

AU - Smith, A.

AU - Walker, I.

AU - Yee, K.

PY - 2002/4/16

Y1 - 2002/4/16

N2 - The Hematology Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative has systematically reviewed the published literature and, through a consensus process, developed an evidence-based practice guideline assessing the role of stem-cell transplantation in patients with multiple myeloma. The conclusions were validated by solicited feedback from 221 practitioners across Ontario, Canada. The guideline comprises six recommendations: 1) Autologous transplantation is recommended for patients with stage II or III myeloma and good performance status. Evidence of benefit is strongest for patients who are younger than 55 years of age and have a serum creatinine level less than 150 μmol/L (<1.7 mg/dL). Physicians must use clinical judgment in recommending transplantation to other patients. 2) Allogeneic transplantation is not recommended as routine therapy. 3) Patients potentially eligible for transplantation should be referred for assessment early after diagnosis and should not be extensively exposed to alkylating agents before collection of stem cells. 4) Autologous peripheral blood stem cells should be harvested early in the patient's treatment course. The best available data suggest that transplantation is most advantageous when performed as part of initial therapy. 5) The comparative data addressing the specifics of the transplantation process are insufficient to allow definitive recommendations. In the absence of such data, a single transplant with high-dose melphalan, with or without total-body irradiation, is suggested for patients undergoing transplantation outside a clinical trial. 6) At this time, no conclusions can be reached about the role of interferon therapy after transplantation.

AB - The Hematology Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative has systematically reviewed the published literature and, through a consensus process, developed an evidence-based practice guideline assessing the role of stem-cell transplantation in patients with multiple myeloma. The conclusions were validated by solicited feedback from 221 practitioners across Ontario, Canada. The guideline comprises six recommendations: 1) Autologous transplantation is recommended for patients with stage II or III myeloma and good performance status. Evidence of benefit is strongest for patients who are younger than 55 years of age and have a serum creatinine level less than 150 μmol/L (<1.7 mg/dL). Physicians must use clinical judgment in recommending transplantation to other patients. 2) Allogeneic transplantation is not recommended as routine therapy. 3) Patients potentially eligible for transplantation should be referred for assessment early after diagnosis and should not be extensively exposed to alkylating agents before collection of stem cells. 4) Autologous peripheral blood stem cells should be harvested early in the patient's treatment course. The best available data suggest that transplantation is most advantageous when performed as part of initial therapy. 5) The comparative data addressing the specifics of the transplantation process are insufficient to allow definitive recommendations. In the absence of such data, a single transplant with high-dose melphalan, with or without total-body irradiation, is suggested for patients undergoing transplantation outside a clinical trial. 6) At this time, no conclusions can be reached about the role of interferon therapy after transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0037117616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037117616&partnerID=8YFLogxK

M3 - Article

C2 - 11955031

AN - SCOPUS:0037117616

VL - 136

SP - 619

EP - 629

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 8

ER -